Shanghai Pharmaceuticals

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Health, FDA, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Epilepsy, TPA, AIS, Patient, Tissue plasminogen activator, Stroke, G&A, Investment, Therapy, Pharmacovigilance, Nektar Therapeutics, Research, KLK1, Biostatistics, NKTR, Trial of the century, DSM-IV codes, NIHSS, Amgen, Data management, Pharmacy, Food, Cubist Pharmaceuticals, Neurology, Rankine scale, Shanghai Pharmaceuticals, DMAC, Acquisition, University, Yale University, Psychiatry, MRS, ASTN, Takeda, Patent, Bangladesh Technical Education Board, Probability, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.
  • Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2023 financial results.
  • Other income, net, was $1.9 million for the year ended December 31, 2023 compared to $0.4 million for 2022.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and full year quarter 2023 financial results on Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time:

Aurora Mobile Wins 2021 Leading SaaS Enterprise Award in the 5th China Software and Information Service Industry Annual Billboard

Retrieved on: 
Wednesday, February 9, 2022
Aurora, NASDAQ, Industry, GLOBE, Private Securities Litigation Reform Act, Shanghai Pharmaceuticals, Forward-looking statement, SMS, Gen, AI, U.S. Securities and Exchange Commission, API, Leading, Algorithm, Acquisition, Solution, Terminology, Company, Annual report, Software as a service, Efficiency, Internet, DingTalk, Security (finance), JG, Video, WeChat, UMS, SDK, Attention, Generation Z, Software, Annual, Communication, Cloud computing, Video game, Mobile phone, Alipay

SHENZHEN, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (Aurora Mobile or the Company), a leading mobile developer service provider in China, today announced that it was recently recognized as the Leading SaaS Enterprise in the 2021 Fifth China Software and Information Service Industry Annual Billboard (the Annual Billboard), an initiative by the Information Observation Network.

Key Points: 
  • SHENZHEN, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (Aurora Mobile or the Company), a leading mobile developer service provider in China, today announced that it was recently recognized as the Leading SaaS Enterprise in the 2021 Fifth China Software and Information Service Industry Annual Billboard (the Annual Billboard), an initiative by the Information Observation Network.
  • Since the Annual Billboard was launched five years ago, it has attracted extensive attention and influence across the industry.
  • Given the Company's excellent performance, Aurora Mobile was selected as the 2021 Leading SaaS Enterprise in China's Software and Information Service Industry, a testament of the industry-wide acclaim and trust that Aurora Mobile commands for its robust technical capabilities and services.
  • Founded in 2011, Aurora Mobile is a leading mobile developer service provider in China.

Aurora Mobile Deepens Cooperation with a Fortune Global 500 Company to Expand Innovation for Medical Services

Retrieved on: 
Thursday, January 13, 2022
Aurora, U.S. Securities and Exchange Commission, Forward-looking statement, Technology, China Everbright Bank, Annual report, UMS, Pharmacy, Wi-Fi, Central government, Nasdaq, JG, Shanghai Pharmaceuticals, SMS, NASDAQ, Bank, SDK, GLOBE, Fortune Global 500, Securities & Exchange Commission of Pakistan, Industry, Private Securities Litigation Reform Act, OA, Company, Software as a service, Efficiency, IOS SDK, WeChat, Ping An Bank, Former Central Government Offices, HUAWEI, Security (finance), DingTalk, Terminology, Mobile phone, Fine chemical, Alipay

SHENZHEN, China, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (Aurora Mobile or the Company), a leading mobile developer service provider in China, today announced that it has deepened cooperation with Shanghai PharmaceuticalsHoldingCo.,Ltd.

Key Points: 
  • SHENZHEN, China, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (Aurora Mobile or the Company), a leading mobile developer service provider in China, today announced that it has deepened cooperation with Shanghai PharmaceuticalsHoldingCo.,Ltd.
  • To address this problem, Aurora Mobile integrated the JG Unification Messaging System (JG UMS) into the OA office app of Shanghai Pharmaceuticals.
  • The team leader at Shanghai Pharmaceuticals commented, As a Fortune Global 500 company, Shanghai Pharmaceuticals has to innovate to enhance our competitiveness in the industry.
  • Aurora Mobile is a leading mobile developer service provider in China and was listed on the Nasdaq Stock Market in 2018.

HUYABIO Announces the Exclusive License of the Wee1 Inhibitor from Shanghai Pharmaceuticals

Retrieved on: 
Tuesday, November 9, 2021
Large-cell lung carcinoma, North China Pharmaceutical Group, SAN, Cancer, CEO, Growth hacking, Protein, Forbes, DNA repair, Research, Global, Program, SPH, Hepatocellular carcinoma, Forbes Global 2000, Neuroblastoma, Company, Hereditary diffuse gastric cancer, Mitosis, Wee1, Shanghai Pharmaceuticals, DNA, Glioblastoma, Fine chemical, Pharmaceutical industry

This is the first program that Shanghai Pharma has outlicensed to a global partner.

Key Points: 
  • This is the first program that Shanghai Pharma has outlicensed to a global partner.
  • "HUYABIO International has pioneered an innovative approach for partnering with Chinese research institutions and pharmaceutical companies.
  • Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO, said, "We are delighted to partner with Shanghai Pharmaceuticals for a therapeutic mechanism that promises broad synergy across treatments for many tumor types.
  • With over 50,000 employees, Shanghai Pharma is looking forward to its solid performance in the near future.

Shanghai Pharmaceuticals and Luca Healthcare Announce a Strategic Collaboration to Provide Home Drug Delivery to Rare Disease Patients on Luca Healthcare's Patient Management Platform

Retrieved on: 
Tuesday, October 12, 2021
Pharmacy, SPH, Fortune, Direct, Physician, Medicine, Shanghai Pharmaceuticals, Fortune Global 500, Luca, Software, Population, Vital signs, Quality of life, Ophthalmology, Degenerative disease, Therapy, Partnership, Patient, Disease, Research, Biomarker, Medical device

"We are delighted to enter into this strategic alliance with Luca Healthcare to provide online physician support and direct access to medication for patients with chronic and rare diseases.

Key Points: 
  • "We are delighted to enter into this strategic alliance with Luca Healthcare to provide online physician support and direct access to medication for patients with chronic and rare diseases.
  • The integration of our internet hospital to drug home delivery ecosystem will bring great convenience and significant value to patients."
  • "China's 20 million rare disease patients have limited options to manage their diseases.
  • Adding Shanghai Pharma's internet hospital platform and a national home drug delivery network will greatly enhance this experience."

Pharma Logistics Wins Department of Defense Contract to Provide Pharmaceutical Reverse Distribution Services

Retrieved on: 
Thursday, April 1, 2021
Contracts, Hospitals, Transport, Other Health, Health, Pharmaceutical, General Health, Logistics, Supply chain management, Defense, Pharma, Shanghai Pharmaceuticals

Pharma Logistics ( www.pharmalogistics.com ), the industry leader in reverse pharmaceutical distribution services, today announced it has secured the Pharmaceutical Reverse Distribution Program (PRDP) with the Department of Defense Continental United States (CONUS) and Outside Continental United States (OCONUS) covering the United States Army, Air Force, Navy and Marines.

Key Points: 
  • Pharma Logistics ( www.pharmalogistics.com ), the industry leader in reverse pharmaceutical distribution services, today announced it has secured the Pharmaceutical Reverse Distribution Program (PRDP) with the Department of Defense Continental United States (CONUS) and Outside Continental United States (OCONUS) covering the United States Army, Air Force, Navy and Marines.
  • Pharma Logistics ability to provide best-in-class on-site services, credit collection, reconciliation and customer support was paramount in the selection for the Department of Defense.
  • In addition to servicing the Department of Defense, Pharma Logistics provides pharmaceutical returns to thousands of hospitals and independent retail pharmacies across the nation.
  • Founded in 1996, Pharma Logistics is the trusted, proven industry leader in reverse pharmaceutical distribution services, including rapid credit, box and ship, onsite and drug take back programs.